Effects of minimal dose aprotinin on blood loss and fibrinolytic system-complement activation in coronary artery bypass grafting surgery.
BACKGROUND
To determine whether 500,000 KIU aprotinin is effective to reduce blood loss in coronary artery bypass grafting (CABG) and to evaluate the effects of this regimen on hematologic parameters.


METHODS
Forty-four patients scheduled for primary CABG were randomly assigned to the aprotinin (n = 24) or control group (n = 20). In aprotinin group, aprotinin was administered in two equal doses (before skin incision and added to the pump prime). Ventilation time, intensive care unit stay, mediastinal tube drainage, hospitalization, transfusion requirements, and postoperative morbidities and mortality were noted. Hematologic markers of fibrinolytic activity and complement activation were also measured pre- and postoperatively.


RESULTS
Although less mediastinal drainage occurred in aprotinin group, the difference was not statistically significant. Other postoperative variables like transfusion requirements, morbidities, and mortality were also found to be similar between groups. Among hematologic parameters, only postoperative levels of alpha2-antiplasmin and plasminogen activator inhibitor-1 were significantly higher in aprotinin group.


CONCLUSIONS
Although plasmin inhibitors begin to rise at this very low aprotinin dosage, it is not advisable to use this aprotinin regimen in CABG patients.
Cicekcioglu
Ferit
F
Cardiovascular Surgery Clinic, Turkiye Yuksek Ihtisas Hospital, Ankara, Turkey.
Cagli
Kerim
K
Emir
Mustafa
M
Topbas
Murat
M
Catav
Zeki
Z
Sener
Erol
E
Tasdemir
Oguz
O
D000328:Adult; D007611:Aprotinin / Q000008:administration & dosage*; D015415:Biomarkers / Q000097:blood; D016063:Blood Loss, Surgical / Q000517:prevention & control*; D001803:Blood Transfusion; D003167:Complement Activation / Q000187:drug effects*; D001026:Coronary Artery Bypass; D003327:Coronary Disease / Q000097:blood / Q000188:drug therapy* / Q000503:physiopathology / Q000601:surgery*; D004305:Dose-Response Relationship, Drug; D005260:Female; D005342:Fibrinolysis / Q000187:drug effects*; D006801:Humans; D008297:Male; D008875:Middle Aged; D019990:Perioperative Care; D015842:Serine Proteinase Inhibitors / Q000008:administration & dosage*; D016896:Treatment Outcome
D015415:Biomarkers; D015842:Serine Proteinase Inhibitors; D007611:Aprotinin